{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:55:04Z","timestamp":1774342504811,"version":"3.50.1"},"reference-count":29,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T00:00:00Z","timestamp":1442534400000},"content-version":"unspecified","delay-in-days":10821,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. j. neurol. sci."],"published-print":{"date-parts":[[1986,2]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title><jats:p>Clinical exacerbations of multiple sclerosis (MS) are characterized by elevated levels of cerebrospinal fluid (CSF) myelin basic protein (MBP). The purposes of this study were to determine whether anti-MBP antibodies are present in increased titer in CSF of MS patients with exacerbations, and whether they can be suppressed by the administration of immunosuppressive dosages of methylprednisolone (MP). A solid phase radio-immunoassay (RIA) was used to detect free and total anti-MBP antibodies before and after acid hydrolysis of CSF. In MS exacerbations, the majority of elevated anti-MBP is in the free form. With the exception of subacute sclerosing panencephalitis (SSPE) and some cases of post infectious encephalomyelitis, anti-MBP antibodies are not present in either MS patients in remission or in non-MS controls. Anti-MBP levels remained elevated over a 10 day period when patients are managed by bed rest only or when treated with intravenous (IV) ACTH. IV administration of MP in \u201chigh\u201d (160 mg\/day) or \u201cmega\u201d (2 g\/day) dosages produces a highly significant reduction of both MBP (p&lt;0.01) and anti-MBP (p&lt;0.001) levels. Total intrathecal IgG synthesis is also significantly suppressed by IV-MP but not by ACTH.<\/jats:p>","DOI":"10.1017\/s0317167100035757","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T07:37:29Z","timestamp":1469691449000},"page":"25-30","source":"Crossref","is-referenced-by-count":30,"title":["Effect of Methylprednisolone on CSF IgG Parameters, Myelin Basic Protein and Anti-Myelin Basic Protein in Multiple Sclerosis Exacerbations"],"prefix":"10.1017","volume":"13","author":[{"given":"Kenneth G.","family":"Warren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Catz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verona M.","family":"Jeffrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy J.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2015,9,18]]},"reference":[{"key":"S0317167100035757_ref010","doi-asserted-by":"publisher","DOI":"10.1038\/287335a0"},{"key":"S0317167100035757_ref003","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(70)90156-5"},{"key":"S0317167100035757_ref005","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410170510"},{"key":"S0317167100035757_ref011","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(80)90035-7"},{"key":"S0317167100035757_ref012","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100045078"},{"key":"S0317167100035757_ref016","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.30.3.240"},{"key":"S0317167100035757_ref019","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1981.tb04399.x"},{"key":"S0317167100035757_ref004","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.28.9_Part_2.76"},{"key":"S0317167100035757_ref015","first-page":"9","article-title":"What is multiple sclerosis? Laboratory criteria for diagnosis","author":"Tourtellotte","year":"1975","journal-title":"Multiple Sclerosis Research"},{"key":"S0317167100035757_ref009","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(72)90105-0"},{"key":"S0317167100035757_ref008","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(79)90010-4"},{"key":"S0317167100035757_ref013","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1983.tb04847.x"},{"key":"S0317167100035757_ref024","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.30.7_Part_2.33"},{"key":"S0317167100035757_ref007","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.27.3.273"},{"key":"S0317167100035757_ref014","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1965.tb20235.x"},{"key":"S0317167100035757_ref017","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410200105"},{"key":"S0317167100035757_ref020","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1983.tb04841.x"},{"key":"S0317167100035757_ref021","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.1.24"},{"key":"S0317167100035757_ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.20.5_Part_2.1","article-title":"Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH versus placebo. Final report","volume":"20","author":"Rose","year":"1970","journal-title":"Neurology"},{"key":"S0317167100035757_ref023","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.30.11.1155"},{"key":"S0317167100035757_ref026","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.45.10.941"},{"key":"S0317167100035757_ref027","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.46.1.99"},{"key":"S0317167100035757_ref028","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410150309"},{"key":"S0317167100035757_ref001","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(48)90389-1"},{"key":"S0317167100035757_ref006","first-page":"334","article-title":"Gel isoelectric focusing of cerebrospinal fluid proteins: A potential diagnostic tool","volume":"9","author":"Delmotte","year":"1971","journal-title":"Z Klin Chem Klin Biochem"},{"key":"S0317167100035757_ref029","first-page":"378","article-title":"Prolonged suppression of CNS IgG synthesis after large dose \u201cpulse\u201d methylprednisolone therapy in multiple sclerosis","volume":"68","author":"Trotter","year":"1979","journal-title":"Neurology"},{"key":"S0317167100035757_ref025","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.45.2.179-a"},{"key":"S0317167100035757_ref018","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1980.00500530044005"},{"key":"S0317167100035757_ref002","doi-asserted-by":"publisher","DOI":"10.3109\/00365517709091498"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167100035757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:13:50Z","timestamp":1558538030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167100035757\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1986,2]]}},"alternative-id":["S0317167100035757"],"URL":"https:\/\/doi.org\/10.1017\/s0317167100035757","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,2]]}}}